Kura Oncology, Inc. $KURA Shares Bought by Armistice Capital LLC

Armistice Capital LLC raised its position in Kura Oncology, Inc. (NASDAQ:KURA) by 5.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 4,936,000 shares of the company’s stock after acquiring an additional 264,000 shares during the quarter. Kura Oncology makes up about 0.6% of Armistice Capital LLC’s holdings, making the stock its 22nd largest holding. Armistice Capital LLC owned approximately 0.06% of Kura Oncology worth $51,285,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. ACT Capital Management LLC acquired a new position in shares of Kura Oncology during the 4th quarter worth $768,000. AQR Capital Management LLC grew its stake in Kura Oncology by 36.6% in the 4th quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock valued at $31,816,000 after acquiring an additional 820,020 shares during the last quarter. Trexquant Investment LP grew its stake in Kura Oncology by 5.7% in the 4th quarter. Trexquant Investment LP now owns 227,382 shares of the company’s stock valued at $2,362,000 after acquiring an additional 12,339 shares during the last quarter. Jump Financial LLC lifted its holdings in Kura Oncology by 1,188.2% in the 4th quarter. Jump Financial LLC now owns 422,443 shares of the company’s stock valued at $4,389,000 after purchasing an additional 389,649 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Kura Oncology by 9.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 45,727 shares of the company’s stock valued at $476,000 after purchasing an additional 3,768 shares in the last quarter.

Kura Oncology Stock Performance

Shares of KURA opened at $9.57 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14. The stock has a market capitalization of $849.53 million, a PE ratio of -2.86 and a beta of 0.36. Kura Oncology, Inc. has a 12-month low of $5.45 and a 12-month high of $12.49. The business’s fifty day moving average price is $9.37 and its 200 day moving average price is $9.26.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.05. The company had revenue of $18.27 million for the quarter, compared to analysts’ expectations of $25.97 million. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%. Equities research analysts forecast that Kura Oncology, Inc. will post -3.47 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a report on Thursday, May 28th. Wells Fargo & Company set a $24.00 price target on shares of Kura Oncology in a report on Thursday, June 4th. Jefferies Financial Group set a $24.00 price objective on shares of Kura Oncology in a research report on Thursday, May 28th. Wedbush lowered their price objective on shares of Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, March 6th. Finally, Zacks Research raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Thursday, February 26th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and an average price target of $25.46.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.